TauC3 Biologics Ltd


TauC3 Biologics is focused on the development of innovative high precision immunotherapy for the treatment of the devastating neurodegenerative diseases known as tauopathies, particularly tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP).

Contact: Daniel G. Chain, PhD, President and CEO

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.